References:

    1.  Soules M et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Menopause: The Journal of The North American Menopause Society, July 2001. Vol. 8, No. 6, pp. 402–407

    2.  North American Menopause Society.  Menopause Practice:  A Clinician’s Guide.  Cleveland, OH:       The North American Menopause Society; 2004.

    3.  Thurston R et al.  Adiposity and Reporting of Vasomotor Symptions among Midlife Women.  American Journal of Epidemiology 2007; 167 (1): 78-85.

    4.  Deecher DC.  Physiology of Thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms.  Expert Opinion Investigating Drugs 2005; 14: 435-448.

    5.  Zoler M.  Nonhormonal Drug Eases Vasomotor Symptoms.  Family Practice News 2007; 37 (14): 26-27.

    6.  Management Of Vasomotor Symptoms During The Menopausal Transition.  Supplement to Journal of Family Practice 2008; Jan S10

    7.  Woods NF, Mitchell ES,  Landis C. Anxiety, hormonal changes, and vasomotor symptoms during the menopause transition. Menopause. 2005 May-Jun;12(3):242-5

    8.  Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S, Ferdousi T. The role of anxiety and hormonal changes in menopausal hot flashes. Menopause. 12(3):258-266, May/June 2005.

    9.  Davis S, Tran J. What are "normal" testosterone levels for women? J Clin Endocrinol Metab. 2001 Apr;86(4):1842-4.

    10.  National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center. Osteoporosis Overview. Accessed via http://www.osteo.org/

    Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003 Oct 1;290(13):1729-38.

    11.  Grodstein F et al.  Hormone Therapy and Coronary Heart Disease:  The Role of Time Since Menopause and Age at Hormone Initiation.  Journal of Womens Health 2006; 15(1): 35-38

    12.  Rossouw J et al.  Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause.  American Medical Association 2007; 297 (13): 1465-1477.

    13.  Freedman R et al.  Sleep Disturbance in Menopause.  Menopause 2007 May; 14(5):  826-829.

    14.  Mold J et al.  Associations Between Subjective Night Sweats and Sleep Study Findings.  JABFM 2008 April; 21(2): 96-103

    16.  Hsia J. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.  Circulation. 2004 Feb 10;109 (5):620-6. 

    17.  Mendelsohn ME, Karas RH.  The Protective Effects of Estrogen on the Cardiovascular System.  New England Journal of Medicine 1999;  340: 1801-11.

    18. Grodstein F et al.  Postmenopausal Hormone Therapy and Stroke.  American Medical Association 2008 April; 168(8):861-66. 

    19.  Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI.  A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001 Oct 25;345(17):1243-9.

    20.  Hogervorst E, Williams J, Combrinck M, David Smith A. Measuring serum oestradiol in women with Alzheimer's disease: the importance of the sensitivity of the assay method. Eur J Endocrinol. 2003 Jan;148(1):67-72.

    21.  Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 1999 Mar 23;52(5):965-70.

    22.  Shlipak MG. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). American Heart Journal. Volume 146, Number 5, November 2003. Copyright © 2003 Mosby, Inc.

    23.  Wenger NK, Weber MA, Scheidt S. Coronary risk attributes, coronary risk reduction, and clinical outcomes. Am J Geriatr Cardiol. 2006 May-Jun;15(3):140-1.

    24.  Budoff MJ, Chen GP, Hunter CJ, Takasu J, Agrawal N, Sorochinsky B, Mao S. Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. Eur J Obstet Gynecol Reprod Biol. 2005 Feb 1;118(2):225-8.

    25.  Humphries KH. Risks and benefits of hormone replacement therapy: The evidence speaks.  Canadian Medical Association Journal. Volume 168, Number 8, April 15, 2003. Copyright © 2003 Canadian Medical Association.

    26.  Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol. 2006 May 2;47(9):1741-53. Epub 2006 Apr 17. Review.

    27.  Postmenopausal Hormone Therapy and Stroke: Role of Time Since Menopause and Age at Initiation of Hormone Therapy. Arch Intern Med. 2008;168(8):861-866.

    28.  Crandall C, Palla S, Reboussin BA, Ursin G, Greendale GA. Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study. Breast Cancer Res. 2005;7(6):R922-8. Epub 2005 Sep 22.

    29.  Villareal DT, Rupich RC, Pacifici R, Griffin MG, Maggio D, Avioli LV, Civitelli R. Effect of estrogen and calcitonin on vertebral bone density and vertebral height in osteoporotic women. Osteoporos Int. 1992 Mar;2(2):70-3.

    30.  Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Maturitas. 2006 Jan 20;53(2):191-200.

    31. Grady D Hormone replacement therapy and endometrial cancer risk: a meta-analysis. - Obstet Gynecol - 01-FEB-1995; 85(2): 304-13

    32.  Yang CH, Lee JN, Hsu SC, Kuo CH, Tsai EM; Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. Maturitas. 2002 Sep 30;43(1):35-9. 

    33.  Sellers T.A., Mink P.J., Cerhan J.R., Zheng W., Anderson K.E., Kushi L.H., Folsom AR. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997 Dec 1;127(11):973-80

    34.  Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control. 1996 Jul;7(4):449-57 

    35.  Daling JR, Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.  Cancer, Volume 95, Issue 12 , Pages 2455 – 2464 

    36.  Pappo I, Meirshon I, Karni T, Siegelmann-Danielli N, Stahl-Kent V, Sandbank J, Wasserman I, Halevy A. The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers. Ann Surg Oncol. 2004 Jan;11(1):52-8. 

    37.  Collins JA.  Current use of estrogen/progestin increased breast cancer risk in postmenopausal women more than estrogen alone Evidence-based Obstetrics & Gynecology, Volume 5, Number 4, December 2003. Copyright © 2003 Churchill Livingstone, Inc. 

    38.  Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA.  Unopposed Estrogen Therapy and the Risk of Invasive Breast Cancer,  Archives of Internal Medicine 2006;166:1027-1032. 

    39.  Creasman WT, Hoel D, Disaia PJ. WHI: Now that the dust has settled. Am J Obstet Gynecol. 2003 Sep;189(3):621-6. Review. 

    40.  Cengiz B, Atabekoglu C, Cetinkaya E, Cengiz SD; Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas. 2003 Dec 10;46(4):301-6 

    41.  Tang YP, Haslam SZ, Conrad SE, Sisk CL. Estrogen increases brain expression of the mRNA encoding transthyretin, an amyloid beta scavenger protein. J Alzheimers Dis. 2004 Aug;6(4):413-20; discussion 443-9. 

    42.  Ho KK, O'Sullivan AJ, Wolthers T, Leung KC. Metabolic effects of oestrogens: impact of the route of administration. Ann Endocrinol (Paris). 2003 Apr;64(2):170-7. Review.           

    43. Janssen Janssen YJ, Helmerhorst F, Frolich M, Roelfsema F.A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. J Clin Endocrinol Metab. 2000 Jan;85(1):464-7. 

    44.  Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ.. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Hematol. 2004 March;124(6):836-40. 

    45.  Savvas M. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ. 1988 Jul 30;297(6644):331-3  

    46.  Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 1995 Apr; 85(4):529-37. Erratum in: Obstet Gynecol 1995 May; 85(5 Pt 1):668. 

    47.  Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005 Apr 10;114(3):448-54 

    48.  de Lignieres B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 2002 Dec;5(4):332-40. 

    49.  Staren E, Omer S. Hormone replacement therapy in postmenopausal women. Am J Surg 2004;188(2):136-49 Review

    50.  Di Spiezio, S A, Radhakrishnan S. Endometrial carcinoma on continuous combined HRT: case report and literature review. Maturitas. 2004 Jun 15;48(2):171-5. 

    51.  Stevenson JC et al.  Randomized trial of effect of transdermal continuous combination hormone replacement therapy on cardiovascular risk markers. Br J Hematol 2004 March;124(6):836-40.  

    52. Shoupe D  HRT dosing regimens:Continuous versus Cyclic—Pros and Cons 

    Int J Fertil  2001;46(1):7-15 

    53.  Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004 May 1;109(5):721-7. 

    54.  Sarrel PM., Sexuality and menopause. Obstet Gynecol. 1990 Apr;75(4 Suppl):26S-30S 

    55..  Gelfand, MM. It might be wise to consider adding androgen to the estrogen or estrogen-progestin regimens in the appropriate patients. Menopause. 2004 Sep-Oct;11(5):505-7.

    56.  Davis S, Tran J. What are "normal" testosterone levels for women? J Clin Endocrinol Metab. 2001 Apr;86(4):1842-4. 

    57.  Miller, K, et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism 2006; 91:1683-1690. 

    58..  Paoletti AM, Congia S, Lello S, Tedde D, Orru M, Pistis M, Pilloni M, Zedda P, Loddo A, Melis GB.  Low androgenization index in elderly women and elderly men with Alzheimer's disease. Neurology. 2004 Jan 27;62(2):301-3. 

    59.  Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease.  Exp Gerontol. 2004 Nov-Dec;39(11-12):1633-9 

    60.  Dimitrakakis C et al.  Breast Cancer Incidence in Postmenopausal Women Using Testosterone in Addition to Usual Hormone Therapy.  The Journal of the North American Menopause Society 2004; 11(5): 531-535. 

    61.  Davis S et al.  Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women.  Annals of Internal Medicine 2008; 148: 569-577 

    62.  Burd ID,  Bachmann GA. Androgen replacement in menopause. Curr Womens Health Rep. 2001 Dec;1(3):202-5. Review. 

    63.  Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005 Jul 25;165(14):1582-9. 

    64.  Davis S, Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005 Sep;90(9):5226-33. Epub 2005 Jul 12 

    65.  Polotysky A, Santoro N.  Menopause and Cardiovascular Disease: Endogenous Reproductive Hormone Exposure Affects Risk Factors.  Menopause 2007. 

    66.  Ross R et al.  Effect of Hormone Replacement Therapy on Brest Cancer Risk: Estrogen vs. Estrogen plus Progestin.  J Natl Cancer Inst  2000;92(4):328-332 

    67.  Mead JH, Lommen ET. Slim, Sane & Sexy Pocket Guide to Natural, Bioidentical Hormone Balancing Calaroga Publishing, Oregon City, Oregon Copyright 2008 p. 43  

    Additional References 

    Davis SR. Postmenopausal hormone-replacement therapy. N Engl J Med. 2002 Jan 3;346(1):63-5. No abstract available. 

    Davis SR.  Determining the effects of androgen therapy on sexual well-being: a complex challenge. Menopause. 2005 Jul-Aug;12(4):359-60. Epub 2005 Jul 21. No abstract available. 

    Davis SR, Dinatale I, Rivera-Woll L, Davison S. Postmenopausal hormone therapy: from monkey glands to transdermal patches.
    J Endocrinol. 2005 May;185(2):207-22. Review. 

    Corrado F, D'Anna R, Caputo F, Cannata ML, Zoccali MG, Cancellieri F. Compliance with hormone replacement therapy in postmenopausal Sicilian women. J Womens Health (Larchmt). 2005 Jun;14(5):410-7. 

    Beral V, Bull D, Reeves G; Million Women Study Collaborators, Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005 Apr 30-May 6;365(9470):1543-51.  

    Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(13):865-83.

    Erkkola R, Kumento U, Lehmuskoski S, Mattila L, Mustonen M, No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years. J Br Menopause Soc. 2004 Mar;10(1):9-13. 

    Palomba S, Sena T, Noia R, Di Carlo C, Zullo F, Mastrantonio P. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstetrics & Gynecology 2001; 98:1053-1058 

    Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA; Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer. 2004 Oct 1;101(7):1490-500.
     

    Prasad R, Boland GP, Cramer A, Anderson E, Knox WF, Bundred NJ; Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer. 2003 Dec 15;98(12):2539-46.

    Kuttenn F, Gerson M. Hormone replacement therapy of menopause, heart and blood vessels. Arch Mal Coeur Vaiss 2001;94:685-689.

    Mendelsohn, ME, Karas, RH.  Molecular and cellular basis of cardiovascular gender differences; Science 2005;308:1583-7. 

    Estrogen Therapy Does Not Appear to Protect Postmenopausal Women from Heart Disease.  News From the AMA, Feb. 16, 2006 

    Hormone Replacement Therapy Increases Bone Mineral Density In Frail Elderly Women. Journal of the American Medical Association, August 15, 2001, Vol. 286, 815  

    Sitruk-Ware R. Progestins and cardiovascular risk models. Steroids 2000; 65:651-658. 

    Gelfand MM, et al. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause. 2003 Jul-Aug;10(4):373 

    Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989 Sep;74(3 Pt 1):398-402.

    Rossouw J et al.  Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause.  American Medical Association 2007; 297 (13): 1465-1477. 

    Both ET and EPT Appear To Increase The Risk of Ischemic Stroke in Postmenopausal Women, But RCT Data Have Not Been Bully Consistent In This Regard.  North American Menopause Society; Marcy/April 2007: 15. 

    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999 Feb 10;281(6):537-44 

    Sarrel PM. Broadened spectrum of menopausal symptom relief. J Reprod Med. 1998 Aug;43(8 Suppl):734-40  

    Basson R. Female sexual response: the role of drugs in the management of sexual dysfunction. Obstet Gynecol. 2001 Sep;98(3):522.